Global Stars in Biotech Industry to Discuss Future Trends

TAIPEI, TAIWAN--(Marketwired - Jul 24, 2014) - Personalized small molecular diagnostic preventive medicine and the development of new medicines have already become important trends in the development of the global biotech industry. The efforts made by Taiwan's biotech companies in these areas are starting to bear fruit, with related products being introduced. Meanwhile, international industrial heavyweights and venture capital firms are bullish that Asia's biotech industry is entering a period of rapid growth. A number of experts in biotech trends have been invited to BioBusiness Asia 2014, which is being held by ITRI. Quintiles, the world's largest contract research organization, expects that Asia will feature rapid growth in the next wave of development in the world's biotech industry, and it forecasts that the next giant in the biotech industry will come from one of Asia's emerging markets. In addition, BioCentury Publications Co-Founder, President & CEO David Flores stated that biotech industry players will want to take advantage of the development and investment opportunities created by a shift in health-related public policy by Asian governments.

There comes a new wave of biotech industry investment throughout the world. The BioBusiness Asia conference has become an indispensable platform for biotech companies and heavy-weighted venture capitalists to connect with the global biotech value chain, and enter the biotech markets of Great Asia through Taiwan. The participants of BioBusiness Asia are from the US, Japan, China, and Europe who come together in Taiwan to seek for cooperation opportunities. It is expected that there will be more than 20 successfully paired up companies in the Business Partnering Session, bringing more than US$10 million output value for the biotech industry.